Interview with Jan Egberts, CEO, OctoPlus N.V.
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Address: Zernikedreef 12, 2333 CL Leiden,Netherlands
Tel: +31 (0)71 524 40 44
OctoPlus is a product-oriented drug delivery company focused on the development of improved pharmaceutical products with less side effects, increased patient compliance and better efficacy. Since our inception in 1995, we have established a successful track record and maintain partnerships with large and small biotech and pharma companies throughout the world.
Our business activities include formulation development services, drug delivery technologies and controlled release product development.
OctoPlus uses its proprietary drug delivery technologies to develop controlled release products for clients.
OctoPlus has developed a number of proprietary drug delivery technologies that facilitate the controlled release of biologically active compounds. Our three main technology platforms enable us to develop tailor-made controlled release formulations for all classes of injectable drug compounds:
OctoDEX®: a dextran-based microsphere delivery technology for proteins and particulate systems.
PolyActive®: a biodegradable polymeric drug delivery system for the controlled release of proteins and lipophilic small molecules.
SynBiosys™: a biodegradable polymeric drug delivery system for the controlled release of peptides and small molecules (in collaboration with Innocore BV).
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
With almost thirty years of experience in the life sciences sector, local Dutch consultancy firm Baggerman Farma Consult offers a wide portfolio of services to its clients in the pharmaceutical…
Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed…
John Verhoeven, Partner and co-founder of Eagle Rock Life Sciences, a Dutch independent consultancy offering a broad range of services to both Dutch and international life sciences companies, explains how…
As Director of the Netherlands’ association for innovative medicines, Gerard Schouw outlines new strategies to enhance the Dutch research climate; foster greater collaboration between all stakeholders and improve public perception…
Manfred Rüdiger (MR), Robbert Van Heekeren (RVH) and Jeroen Rovers (JR), respectively CEO, CFO and CMO of Kiadis Pharma, a Dutch biopharmaceutical company focused on cell-based immunotherapy products for the…
After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms.…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
Despite its diminutive size, the Netherlands has historically carried a large weight in the world because of certain cultural endowments: small but united, entrepreneurial, innovative, and externally oriented. During the…
While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate.…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What…
When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong…
WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the…
See our Cookie Privacy Policy Here
